Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: GlobeNewswire
“6 in ’26” expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment complete ahead of schedule; Part A readouts accelerated, now expected to start in Q2 SKYWAY basket trial enrollment on track across rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA); All readouts expected in 4Q 2026 Kate Tansey Chevlen appointed Chief Commercial Officer (CCO) Strong balance sheet with pro forma cash, cash equivalents, and marketable securities balance of $783M as of September 30, 2025*, anticipated to provide cash runway into the second half of 2028 WALTHAM, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, toda
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics (NASDAQ:SYRE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $70.00 price target on the stock.MarketBeat
- Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics' CEO Sells 15,000 Shares [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswire
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 1/13/26 - Form 4
- 1/13/26 - Form 4
- 1/13/26 - Form 4
- SYRE's page on the SEC website